Reversibility of opioid receptor occupancy of buprenorphine in vivo

European Journal of Pharmacology

Volumn 534, Issue 1-3, 2006, Pages 95-102

  Englberger, Werner ^a   Kögel, Babette ^a   Friderichs, Elmar ^a   Straßburger, Wolfgang ^a   Germann, Tieno ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Analgesia; Buprenorphine; Opioid receptor binding; Pseudoirreversible binding

Indexed keywords

BUPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE];

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOREBRAIN; HYPOTHESIS; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

ACETIC ACID; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAVENOUS; KINETICS; MODELS, ANIMAL; MORPHINE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 33644908459     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.01.022     Document Type: Article

References (52)

1. M.M. Belcheva, J. Barg, R.J. McHale, S. Dawn, M.T. Ho, E. Ignatova, and C.J. Coscia Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine Mol. Pharmacol. 44 1993 173 179
2. M.M. Belcheva, M.T. Ho, E. Ignatova, L.B. Jefcoat, J. Barg, Z. Vogel, R.J. McHale, F.E. Johnson, and C.J. Coscia Buprenorphine differentially alters opioid receptor adaptation in rat brain regions J. Pharmacol. Exp. Ther. 277 1996 1322 1327
3. R.A. Boas, and J.W. Villiger Clinical actions of fentanyl and buprenorphine Br. J. Anaesth. 57 1985 192 196
4. T.F. Burke, T.F. Woods, J.W. Lewis, and F. Medzihradsky Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice J. Pharmacol. Exp. Ther. 271 1994 715 721
5. K. Chan, M. Brodsky, T. Davis, S. Franklin, C.E. Inturrissi, and B.C. Yoburn The effect of the irreversible μ-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA Eur. J. Pharmacol. 287 1995 135 143
6. C. Chen, J.-C. Xue, J. Zhu, Y.-W. Chen, S. Kunapuli, J.K. de Riel, L. Yu, and L.-Y. Liu-Chen Characterization of irreversible binding of β-funaltrexamine to the cloned rat μ opioid receptor J. Biol. Chem. 270 1995 17866 17870
7. 3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor J. Biol. Chem. 271 1996 21422 21429
8. T. Christoph, B. Kögel, K. Schiene, M. Méen, J. De Vry, and E. Friderichs Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain Eur. J. Pharmacol. 507 2005 87 98
9. S.D. Comer, T.F. Burke, J.W. Lewis, and J.H. Woods Clocinnamox: a novel, systemically-active, irreversible opioid antagonist J. Pharmacol. Exp. Ther. 262 1992 1051 1056
10. A. Cowan Update on the general pharmacology of buprenorphine A. Cowan J.W. Lewis Buprenorphine: combatting drug abuse with a unique opioid 1995 Wiley-Liss New York 31 47
11. F.E. D'Amour, and D.L. Smith A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 72 1941 74 78
12. J. Dum, J. Bläsig, and A. Herz Buprenorphine: demonstration of physical dependence liability Eur. J. Pharmacol. 70 1981 293 300
13. W. Englberger, E. Friderichs, T. Germann, and W. Strassburger In vitro and ex vivo reversibility of the opioid receptor binding of buprenorphine 4th Congress of the European Federation of IASP Chapters (EFIC), Sept 2-6, Praque Czech Republic 2003 223
14. 11C]methyl]buprenorphine in baboon brain Nucl. Med. Biol. 23 1996 325 331
15. M.G.C. Gillan, and H.W. Kosterlitz Spectrum of the μ-, δ-, and κ-binding sites in homogenates of rat brain Br. J. Pharmacol. 77 1982 461 469
16. S. Gopal, T.B. Tzeng, and A. Cowan Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine Eur. J. Pharmacol. 15 2002 287 293
17. M.K. Greenwald, C.-E. Johanson, D.E. Moody, J.H. Woods, M.R. Kilbourn, R.A. Koeppe, C.R. Schuster, and J.-K. Zubieta Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentration, and antagonist blockade in heroin-dependent volunteers Neuropsychopharmacology 28 2003 2000 2009
18. P. Huang, G.B. Kehner, A. Cowan, and L.Y. Liu-Chen Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist J. Pharmacol. Exp. Ther. 297 2001 688 695
19. S. Ide, M. Minami, G.R. Uhl, I. Sora, and K. Ikeda Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice Neuropharmacology 29 2004 1656 1663
20. R.E. Johnson, P.J. Fudala, and R. Payne Buprenorphine: considerations for pain management J. Pain Symptom Manage. 29 2005 297 326
21. 1-opioid receptors Life Sci. 56 1995 PL285 PL290
22. T. Koch, A. Widera, K. Bartzsch, S. Schulz, L.O. Brandenburg, N. Wundrack, A. Beyer, G. Grecksch, and V. Höllt Receptor endocytosis counteracts the development of opioid tolerance Mol. Pharmacol. 67 2005 280 287
23. B. Kögel, T. Christoph, W. Straβburger, and E. Friderichs Interaction of buprenorphine with μ-opioid receptor agonists and antagonists Eur. J. Pain 9 2005 599 611
24. H.W. Kosterlitz, F.M. Leslie, and A.A. Waterfield Rates of onset and offset of narcotic analgesics in isolated preparations Eur. J. Pharmacol. 32 1975 10 16
25. J.D Leander Buprenorphine has potent kappa opioid receptor antagonist activity Neuropharmacology 26 1987 1445 1447
26. K. Lutfy, and A. Cowan Buprenorphine: a unique drug with complex pharmacology Curr. Neuropharmacol. 2 2004 395 402
27. K. Lutfy, S. Eitan, C.D. Bryant, Y.C. Yang, N. Saliminejad, W. Walwyn, B.L. Kieffer, H. Takeshima, F.I. Carroll, N.T. Maidment, and C.J. Evans Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J. Neurosci. 23 2003 10331 10337
28. L.E. Mather Opioid pharmacokinetics in relation to their effects Anaesth. Intens. Care 15 1987 15 22
29. 3H]DAMGO binding to rat brain sections J. Pharmacol. Exp. Ther. 267 1993 506 514
30. T.F. Meert, and H.A. Vermeirsch A preclinical comparison between opioids: antinociceptive versus adverse effects Pharmacol. Biochem. Behav. 80 2005 309 326
31. M. Ohtani, H. Kotaki, Y. Sawada, and T. Iga Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling J. Pharmacol. Exp. Ther. 272 1995 505 510
32. 3H]DAMGO binding in rats Eur. J. Pharmacol. 337 1997 27 34
33. L.D. Recht, and G.W. Pasternak Effects of β-funaltrexamine on radiolabelled opioid binding Eur. J. Pharmacol. 140 1987 209 214
34. D.W. Raisch, C.L. Fye, K.D. Boardman, and M.R. Sather Opioid dependence treatment, including buprenorphine/naloxone Ann. Pharmacother. 36 2002 312 321
35. T. Reisine, and G.I. Bell Molecular biology of opioid receptors Trends Neurosci. 16 1993 506 510
36. M.L. Richards, and W. Sadée In vivo opiate receptor binding of oripavines to μ, δ and κ sites in rat brain as determined by an ex vivo method Eur. J. Pharmacol. 114 1985 343 353
37. R.B. Rothman, Q. Ni, and H. Xu Buprenorphine: a review of the binding literature A. Cowan J.W. Lewis Buprenorphine: Combatting Drug Abuse with a Unique Opioid 1995 Wiley-Liss New York 19 29
38. W. Sadée, J.S. Rosenbaum, and A. Herz Buprenorphine: differential interaction with opiate receptor subtypes in vivo J. Pharmacol. Exp. Ther. 223 1982 157 162
39. K. Schuh, S.L. Walsh, and M.L. Stitzer Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans Psychopharmacology 145 1999 162 174
40. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk Measurement of protein using bicinchoninic acid Anal. Biochem. 150 1985 76 85
41. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 47 1995 848 854
42. T.M. Tzschentke Behavioural pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction Psychopharmacology 161 2002 1 16
43. J.W. Villiger, and K.M. Taylor Buprenorphine: characteristics of binding sites in the rat central nervous system Life Sci. 29 1981 2699 2708
44. S.J. Ward, D.S. Fries, D.L. Larson, P.S. Portoghese, and A.E. Takemori Opioid receptor binding characteristics of the non-equilibrium μ antagonist β-funaltrexamine (β-FNA) Eur. J. Pharmacol. 107 1985 323 330
45. S. Wnendt, T. Krüger, E. Janocha, D. Hildebrandt, and W. Englberger Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay Mol. Pharmacol. 56 1999 334 338
46. N. Yabaluri, and F. Medzihradsky Down-regulation of μ-opioid receptor by full but not partial agonists is independent of G protein coupling Mol. Pharmacol. 52 1997 896 902
47. A. Yassen, E. Olofsen, A. Dahan, and M. Danhof Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics J. Pharmacol. Exp. Ther. 313 2005 1136 1149
48. G. Zernig, E.R. Butelmann, J.W. Lewis, E.A. Walker, and J.H. Woods In vivo determination of mu opioid receptor turnover in Rhesus monkeys after irreversible blockade with clocinnamox J. Pharmacol. Exp. Ther. 269 1994 57 65
49. G. Zernig, T. Burke, J.W. Lewis, and J.H. Woods Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioural assays J. Pharmacol. Exp. Ther. 279 1996 23 31
50. 35S] GTPγS binding to membranes: determination of potencies and efficacies of ligands J. Pharmacol. Exp. Ther. 282 1997 676 684
51. M. Zimmermann Ethical guidelines for investigations of experimental pain in conscious animals Pain 16 1983 109 110
52. J.-K. Zubieta, M.K. Greenwald, U. Lombardi, J.H. Woods, M.R. Kilbourn, D.M. Jewett, R.A. Koeppe, C.R. Schuster, and C.-E. Johanson Buprenorphine- induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study Neuropsychopharmacology 23 2000 326 334